Archive | April, 2014

Dr. Michael Har-Noy Reviews The Activation Phase Of His CRCL-AlloVaxTM Protocol (Part 2)

15 Apr

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., says that the AlloStim™ infusion results in the activation of memory T-cells, causing them to leave the patient’s circulation and to migrate to the areas of the body where the malignant tumors are located. Prior to the intravenous infusion of AlloStimTM, a sample of blood is taken from each study patient. Another blood sample is drawn 24 to 48 hours after the infusion. Dr. Michael Har-Noy says that these patient blood samples will be analysed in order to verify that the patient’s memory cells have left the patient’s circulation. The intravenous dose of AlloStim™ activates the patient’s immune system, which then can kill the cancer cells. Dr. Michael Har-Noy adds that the intravenous AlloStimTM also provides another fresh source of tumor antigens for that can be processed by the patient’s dendritic cells. Tumor-specific and foreign antigen-specific memory cells of the patient’s immune system travel to the tumor sites and create an extremely inflammatory microenvironment.   Dr. Michael Har-Noy says once this inflammatory microenvironment is established, the patient’s natural immune processes then cascade to generate even more circulating tumor-specific memory T-cells.

Additionally, says Dr. Michael Har-Noy, the patient’s immune system perceives the intravenous AlloStim™ infusion as a massive infection by foreign cellular material. This perception precipitates a powerful rejection response that results in the development of a ‘cytokine storm’. This cytokine storm then maintains a highly inflammatory immune environment, often for several months. Dr. Michael Har-Noy adds that this inflammatory environment can disable a tumor’s immune avoidance mechanism and can switch off suppressor cells which tend to stop tumor destruction by the patient’s immune system. Dr. Michael Har-Noy concludes by saying that this environment created by the AlloStimTM is ideal for the patient’s immune system to eliminate malignancies or to dramatically slow their growth.

Readers can find further information about Dr. Michael Har-Noy’s phase I/II CRCL-AlloVaxTM protocol and his Compassionate Use program in Bangkok, Thailand at www.immunocare.net .

Dr. Michael Har-Noy Describes The Activation Phase Of His CRCL-AlloVaxTM Study Protocol (Part 1)

11 Apr

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., says that the activation phase on day 28 of the Chaperone Rich Cell Lysate (CRCL)-AlloVaxTM protocol is designed to awaken the memory type 1 T-helper cells (Th1 cells) and cytotoxic T lymphocyte (CTL) killer cells that were formed during the earlier priming and vaccination phases of the study protocol. These new Th1 and CTL cells are known as adaptive immune cells. Dr. Michael Har-Noy goes on to say that the activation phase of the study enables these adaptive immune cells to exit the circulation and travel to the sites of the patient’s tumor. Additionally, the activation phase of the protocol conditions the microenvironment of the malignant tumor to facilitate immune-mediated tumor killing by both the adaptive immune Th1 and CTL cells as well as by the patient’s innate natural killer cells and macrophages. Furthermore, says Dr. Michael Har-Noy, this phase is designed to disable the tumor’s ability to escape attack by the patient’s immune system. Dr. Michael Har-Noy points out that the combination of these mechanisms is what renders the CRCL-AlloStim™ anti-tumor vaccine unique among all other tumor vaccines and treatments.

The unique characteristics of AlloStim™, says Dr. Michael Har-Noy, permit all these diverse immune mechanisms to occur together. An intravenous infusion of AlloStim™ is given to the study patient on day 28 of the protocol in order to engage and maximize the full potential of the compound’s special properties. Dr. Michael Har-Noy says that the AlloStim™ cells are suspended in five milliliters of formulation media, and are then slowly infused over a five to ten minute period. The study patient’s vital signs are continuously monitored during the infusion and for at least two hours afterward in order to monitor for any adverse effects or reactions. Dr. Michael Har-Noy says that the most common side effect of the infusion is a syndrome of flu-like symptoms four to 24 hours after the AlloStimTM administration. These symptoms, which include fever, chills and sweating, usually subside within the first 48 hours after the infusion.

Readers should visit www.immunocare.net for further information about Dr. Michael Har-Noy’s phase I/II CRCL-AlloVaxTM protocol and his Compassionate Use program in Bangkok, Thailand.

Dr. Michael Har-Noy Details The Vaccination Phase Of His Phase I/II CRCL-AlloVaxTM Study Protocol (Part 2)

7 Apr

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., tells us that the vaccination process of the Chaperone Rich Cell Lysate (CRCL)-AlloVaxTM study protocol involves the intradermal administration of AlloStimTM to the patient, followed immediately by the intradermal injection of CRCL at the same location on the skin. The first injection is given on day 11 of the protocol. Then, says Dr. Michael Har-Noy, three days afterward (day 14 of the study protocol), an additional intradermal dose of AlloStim™ is given in the same location, followed immediately by another CRCL dose. This two day vaccination protocol is then repeated in a new location on day 18 of the protocol, when AlloStim™ is again injected intradermally and is again followed by a CRCL dose. Lastly, says Dr. Michael Har-noy, the process is repeated a fourth time on day 21. This time, the AlloStimTM is injected and then followed by CRCL, both given at the same location as on day 18.

Dr. Michael Har-Noy says that the AlloStim™ and CRCL intradermal injection site is photographed before and after each dose is administered. Usually, swelling and redness occurs at the injection site, indicating that cellular immunity is present and active. This immune response to the injections is classified as a “Delayed Type Hypersensitivity” reaction or “DTH” response. Thus, says Dr. Michael Har-Noy, by measuring the size of the redness around the rejection site, one can visibly confirm that the vaccination phase was effective.

Dr. Michael Har-Noy adds that on the 25th day of the study protocol, the DTH response is used to determine if the patient has mounted a cellular immune response to both the foreign antigens in AlloStim™ and the tumor antigens in the CRCL. To determine if these responses have indeed occurred, first AlloStim™ is injected intradermally in one location and then CRCL alone without AlloStim™ is given intradermally in a second area. Dr. Michael Har-Noy says that within 48 hours of these separate AlloStim™ and CRCL injections, a DTH response should be seen at both locations, thus indicating that successful induction of the patient’s cellular immunity has occurred.

Please visit www.immunocare.net for more information about Dr. Michael Har-Noy’s phase I/II CRCL-AlloVaxTM study protocol and his Compassionate Use program in Bangkok, Thailand.

Dr. Michael Har-Noy Describes The Vaccination Phase Of His CRCL-AlloVaxTM Study Protocol (Part 1)

4 Apr

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., says that the vaccination phase of his CRCL-AlloVaxTM study protocol falls between Days 11 and 21. This vaccination phase is engineered to produce immunity against the patient’s own cancer cells. Dr. Michael Har-Noy says we know that anti-tumor vaccines need a powerful adjuvant effect to create an effective anti-tumor immune response and to imprint this response over the previous one that originally failed to protect the patient against progression of the tumor.

Dr. Michael Har-Noy adds that in order to create this strong adjuvant effect, both the properties of AlloStim™ and the previously primed status of the patient are used. First, AlloStim™ is again administered to the patient by intradermal injection. This repeat AlloStim™ dose precipitates a powerful rejection response led by the type 1 T-helper (Th1) and cytotoxic T-lymphocyte (CTL) memory cells that were created during the previous priming phase of the study protocol. Next, says Dr. Michael Har-Noy, the Chaperone Rich Cell Lysate (CRCL) is injected into this highly inflammatory environment. CRCL contains chaperone proteins that were isolated from the patient’s own tumor cells. These chaperone proteins express many tumor antigens. When the patient’s skin Langerhans cells migrate to clean up the waste products from the rejection of the foreign AlloStim™, they also begin to process the tumor antigens from the CRCL. Dr. Michael Har-Noy says that this tricks the patient’s immune system into believing that the tumor antigens are really part of the recognized foreign antigens in the AlloStim™. Therefore, says Dr. Michael Har-Noy, each exposure of the patient’s immune system to similar tumor antigens and foreign antigens results in the release into the circulation of increased memory Th1 and CTL cells that are specific for these same tumor and foreign antigens.

For more information about Dr. Michael Har-Noy’s phase I/II CRCL-AlloVaxTM study protocol and his Compassionate Use program in Bangkok, Thailand, please visitwww.immunocare.net .